Background A SARS-CoV-2 protein-based heterodimer vaccine, PHH-1V, has been shown
to be safe and well-tolerated in healthy young adults in a first-in-human, Phase I/IIa study …

Since the genetic sequence of SARS-CoV-2 became available in January 2020, new
vaccines have been developed at an unprecedented speed. The current vaccines have been …

Current COVID-19 vaccines have been associated with a decline in infection rates, prevention
of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are …

The continuing high global incidence of COVID-19 and the undervaccinated status of billions
of persons strongly motivate the development of a new generation of efficacious vaccines. …

In response to COVID-19 pandemic, we have launched a vaccine development program
against SARS-CoV-2. Here we report the safety, tolerability, and immunogenicity of a …

Background We report safety, tolerability, and immunogenicity of a recombinant protein RBD-fusion
heterodimeric vaccine against SARS-CoV-2 (PHH-1V). Methods A dose-escalation, …

SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously
striking with an unpredictable evolution. Despite the success in vaccine production and mass …

The HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority
phase IIb clinical trial to compare the immunogenicity and safety of a heterologous …

Context: Osona is a Catalonian county with almost 157.000 inhabitants, of which 2.9% are
85 years old or over, and it behaves like a micro health system in the Catalan territory. Local …

La presència de blocs de tsunami i de tempesta a les costes rocoses de les Illes Balears
fou un tema desconegut una dècada enrere. L’estudi i caracterització dels “camellones de …